Eli Lilly’s crop of new products propelled the company to 8% sales growth in the fourth quarter, but the most pleasing aspect for the firm was likely the resilience of its diabetes blockbus
Novo Nordisk’s Ozempic (semaglutide) weekly GLP-1 injection has gained a new US indication after the FDA agreed a label extension to cover reducing the risk of cardiac events in adults with
Eli Lilly is targeting a deal worth between $1 billion to $5 billion every quarter in 2020 as it seeks to build its R&D pipeline, its chief financial officer has said.
